Nektar Therapeutics buy Jefferies Financial Group Inc.
Start price
11.04.25
/
50%
€0.56
Target price
11.04.26
€1.77
Performance (%)
4.96%
End price
12.04.26
-
Summary
This prediction is currently being closed. The BUY prediction by Jefferies_Financial_ shows slight gains of 4.96%. Jefferies_Financial_ has 50% into this predictionNektar is a clinical-stage biopharmaceutical company focused on developing treatments for cancer, autoimmune diseases, and chronic pain. The company's pipeline includes product candidates based on its proprietary drug delivery technology, which improves the delivery and effectiveness of drugs in the body. Some of its most advanced candidates include NKTR-214, a cancer immunotherapy, and NKTR-181, a non-opioid pain medication. Nektar is listed on the NASDAQ exchange under the ticker symbol NKTR.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Nektar Therapeutics | - | - | - |
| iShares Core DAX® | -1.741% | 5.979% | 8.977% |
| iShares Nasdaq 100 | 2.815% | 11.827% | 38.406% |
| iShares Nikkei 225® | -0.109% | 11.692% | 46.680% |
| iShares S&P 500 | 0.966% | 7.616% | 28.141% |
Comments by Jefferies_Financial_ for this prediction
In the thread Discuss Nektar Therapeutics
Nektar Therapeutics (NASDAQ: NKTR) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating. They now have a $2.00 price target on the stock, up previously from $1.00.
Ratings data for NKTR provided by MarketBeat
In the thread Trading Nektar Therapeutics
Die von Jefferies_Financial_ gewählte maximale Laufzeit wurde überschritten